Skip to main content
OpenTrials
Completed

NCT Number: NCT02526745

Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older

This study evaluates the safety and immunogenicity of live attenuated vaccine in adults aged 50 years and older. Half of participants will receive high doses of the vaccine,while the other half will receive low doses of the vaccine in phase I clinical trial. At the phase II clinical trial, participants will be distributed equally to four groups(low、middle, high doses of the vaccine and placebo).

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 50 years and older,no vaccine contraindications;
  • Subject to comply with the requirements of clinical trial programs;
  • No immune globulin vaccination history within a month, no vaccination history within 28 days;
  • Axillary temperature ≤37.0 ℃;
  • Patients with chronic diseases should be in stable ;
  • Postmenopausal or female subjects is no longer the possibility of pregnancy, or subjects pregnancy test was negative and has no pregnancy planner during the clinical trial period;
  • The value of blood routine (WBC, RBC, Hb) is normal , or abnormal but meaningless by clinicians judgment ;
  • Alanine aminotransferase (ALT) values is normal, or abnormal but meaningless by clinicians judgment ;
  • Renal function (serum urea nitrogen) is normal, or abnormal but meaningless by clinicians judgment.

Exclusion criteria

  • Allergies, seizures, epilepsy, encephalopathy and other medical history or family history of mental illness;
  • Subjects who is allergic to any element of the vaccine,and have a history of severe allergy to any vaccine;
  • Subjects who is suffering from immune deficiency, receiving immunosuppressive therapy or immunocompromised due to HIV;
  • Subjects who had a history of herpes zoster five years ago;
  • Varicella or herpes zoster vaccination history;
  • Pregnant or lactating women;
  • Women who are planning a pregnancy in the near future;
  • Any prior administration of vaccine in last 28 days or planned to vaccinate any vaccine during the observation period;
  • Suffering from acute febrile diseases, and infectious diseases;
  • Thrombocytopenia or other coagulation disorder history, which may cause subcutaneous taboo;
  • Accept any other investigational drug users within two months;
  • Subjects had high fever (axillary temperature ≥38.0 ℃) in the past three days ;
  • The value of blood routine (WBC, RBC, Hb) is abnormal and meaning by clinicians judgment ;
  • Alanine aminotransferase (ALT) values is abnormal and meaning by clinicians judgment ;
  • Renal function (serum urea nitrogen) is abnormal and meaning by clinicians judgment.
  • Blood pressure is abnormal after medication control;
  • Known or suspected diseases including: respiratory diseases, acute infection or chronic disease , and cardiovascular disease, kidney disease, skin disorders in the acute phase;
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.

Treatment and study plan

the vaccine with high doses of virus content between 4.7~5.0 lgPFU

Biological

the vaccine with low doses of virus content between 4.7~5.0 lgPFU

Biological

the vaccine with high doses of virus content between 4.3~5.0 lgPFU

Biological

the vaccine with middle doses of virus content between 4.3~5.0 lgPFU

Biological

the vaccine with low doses of virus content between 4.3~5.0 lgPFU

Biological

Placebo

Biological

Primary outcomes

  1. Evaluate the Rate of Adverse reactions of live attenuated Herpes zoster Vaccine in Chinese Adults.

    Time frame: 42 days

    Adverse reactions associated with vaccine will be observed in Chinese Adults ( 50 years and older) after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy

Secondary outcomes

  1. Evaluate the seroconversion rate of anti-herpes zoster virus antibodies in serum of adults after vaccination.

    Time frame: 6 months

    The seroconversion rate of anti-herpes zoster virus antibodies will be evaluated in serum of adults within the first 42 days after vaccination.

Sponsors and collaborators

Lead sponsor

Beijing Chaoyang District Centre for Disease Control and Prevention

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
First posted
Aug 18, 2015
Registry last updated
Aug 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.